ACTRIMS 2023 | Cladribine treatment patterns in MS patients: a cross-sectional survey

Emily Evans, MD, MBE, EMD Serono, Rockland, MD, shares the results of a cross-sectional survey evaluating cladribine tablets treatment patterns among patients with multiple sclerosis (MS) across the US enrolled in the MS LifeLines patient support program. Information collected included demographics, clinical characteristics, MS treatment history, prior disease-modifying therapies (DMTs), and cladribine tablets treatment patterns. Switches to cladribine tablets occurred from oral, self-injectable, and infusion DMTs. Very few patients discontinued the cycle or required a switch to another DMT before cladribine tablets completion. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.